Biomarkers in MedicineVol. 6, No. 1 General content - EditorialCardiac myosin binding protein-C: a potential early-stage, cardiac-specific biomarker of ischemia-reperfusion injurySakthivel SadayappanSakthivel SadayappanDepartment of Cell & Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA. Search for more papers by this authorEmail the corresponding author at ssadayappan@lumc.eduPublished Online:2 Feb 2012https://doi.org/10.2217/bmm.11.100AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cardiac biomarkercardiac myosin binding protein-Ccardiac troponin-IMeso Scale Discoverymyocardial infarctionselective reaction monitoringPapers of special note have been highlighted as: ▪ of interestReferences1 Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation123(4),e18–e209 (2011).Crossref, Medline, Google Scholar2 Antman EM, Hand M, Armstrong PW et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation117(2),296–329 (2008).Crossref, Medline, Google Scholar3 McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am. J. Med.124(1),40–47 (2011).Crossref, Medline, Google Scholar4 Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation116(7),e148–e304 (2007).Medline, Google Scholar5 Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation123(18),2022–2060 (2011).Crossref, Medline, Google Scholar6 Mehta SR, Granger CB, Boden WE et al. Early versus delayed invasive intervention in acute coronary syndromes. N. Engl. J. Med.360(21),2165–2175 (2009).Crossref, Medline, CAS, Google Scholar7 Thygesen K, Alpert JS, White HD et al. Universal definition of myocardial infarction. Circulation116(22),2634–2653 (2007).Crossref, Medline, Google Scholar8 Keller T, Zeller T, Peetz D et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med.361(9),868–877 (2009).Crossref, Medline, CAS, Google Scholar9 Reichlin T, Hochholzer W, Bassetti S et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl. J. Med.361(9),858–867 (2009).Crossref, Medline, CAS, Google Scholar10 Govindan S, McElligott A, Muthusamy S et al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J. Mol. Cell Cardiol.52(1),154–164 (2011).▪ There is a need to identify early biomarkers that can reliably rule out acute coronary syndrome, yet detect myocardial ischemia in the absence of irreversible myocyte injury. This report aims for the first time to determine the efficacy of cardiac myosin binding protein-C, a sarcomeric cardiac-specific thick filament assembly protein, as an early circulatory biomarker for myocardial infarction. Many additional studies will be necessary to establish cardiac myosin binding protein-C as a true biomarker for heart attacks.Crossref, Medline, Google Scholar11 Sadayappan S, Gulick J, Osinska H et al. Cardiac myosin binding protein-C phosphorylation and cardiac function. Circ. Res.97(11),1156–1163 (2005).Crossref, Medline, CAS, Google Scholar12 Sadayappan S, Robbins J. The death of transcriptional chauvinism in the control and regulation of cardiac contractility. Ann. NY Acad. Sci.1123,1–9 (2008).Crossref, Medline, CAS, Google Scholar13 Sadayappan S, Osinska H, Klevitsky R et al. Cardiac myosin binding protein-C phosphorylation is cardioprotective. Proc. Natl Acad. Sci. USA103(45),16918–16923 (2006).Crossref, Medline, CAS, Google Scholar14 Sadayappan S, Gulick J, Klevitsky R et al. Cardiac myosin binding protein-C phosphorylation in a {β}-myosin heavy chain background. Circulation119(9),1253–1262 (2009).Crossref, Medline, CAS, Google Scholar15 Sadayappan S, Gulick J, Osinska H et al. A critical function for Ser-282 in cardiac myosin binding protein-C phosphorylation and cardiac function. Circ. Res.109(2),141–150 (2011).Crossref, Medline, CAS, Google Scholar16 Tong CW, Stelzer JE, Greaser ML, Powers PA, Moss RL. Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ. Res.103(9),974–982 (2008).Crossref, Medline, CAS, Google Scholar17 Luther PK, Winkler H, Taylor K et al. Direct visualization of myosin-binding protein C bridging myosin and actin filaments in intact muscle. Proc. Natl Acad. Sci. USA108(28),11423–11428 (2011).Crossref, Medline, CAS, Google Scholar18 Van Eyk JE. Overview: the maturing of proteomics in cardiovascular research. Circ. Res.108(4),490–498 (2011).Crossref, Medline, CAS, Google Scholar19 Meng Z, Veenstra TD. Targeted mass spectrometry approaches for protein biomarker verification. J. Proteomics74(12),2650–2659 (2011).Crossref, Medline, CAS, Google Scholar20 Sheng S, Skalnikova H, Meng A et al. Intact protein separation by one- and two-dimensional liquid chromatography for the comparative proteomic separation of partitioned serum or plasma. Methods Mol. Biol.728,29–46 (2011).Crossref, Medline, CAS, Google Scholar21 Rodriguez H, Rivers R, Kinsinger C et al. Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective. Proteomics Clin. Appl.4(12),904–914 (2010).Crossref, Medline, CAS, Google Scholar22 Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk JE. Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin. Appl.4(3),271–284 (2010).Crossref, Medline, CAS, Google Scholar23 Fu Q, Zhu J, Van Eyk JE. Comparison of multiplex immunoassay platforms. Clin. Chem.56(2),314–318 (2010).Crossref, Medline, CAS, Google Scholar24 Toyama A, Nakagawa H, Matsuda K et al. Deglycosylation and label-free quantitative LC-MALDI MS applied to efficient serum biomarker discovery of lung cancer. Proteome Sci.9,18 (2011).Crossref, Medline, CAS, Google Scholar25 Van Den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.878(5–6),590–602 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByThe role of cardiac biochemical markers in aortic stenosis22 February 2016 | Biomarkers, Vol. 21, No. 4Modifications of myofilament protein phosphorylation and function in response to cardiac arrest induced in a swine model16 July 2015 | Frontiers in Physiology, Vol. 6Surviving the infarct: A profile of cardiac myosin binding protein‐C pathogenicity, diagnostic utility, and proteomics in the ischemic myocardium14 July 2014 | PROTEOMICS – Clinical Applications, Vol. 8, No. 7-8Top-down mass spectrometry of cardiac myofilament proteins in health and disease15 August 2014 | PROTEOMICS - Clinical Applications, Vol. 8, No. 7-8Release kinetics of circulating cardiac myosin binding protein-C following cardiac injuryAmerican Journal of Physiology-Heart and Circulatory Physiology, Vol. 306, No. 4Cardiac myosin binding protein-C as a central target of cardiac sarcomere signaling: a special mini review series7 November 2013 | Pflügers Archiv - European Journal of Physiology, Vol. 466, No. 2Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro17 April 2012 | Journal of Muscle Research and Cell Motility, Vol. 33, No. 1 Vol. 6, No. 1 Follow us on social media for the latest updates Metrics Downloaded 250 times History Published online 2 February 2012 Published in print February 2012 Information© Future Medicine LtdKeywordscardiac biomarkercardiac myosin binding protein-Ccardiac troponin-IMeso Scale Discoverymyocardial infarctionselective reaction monitoringAcknowledgementsThe author wishes to thank F Leya, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA, and C Tong, Scott and White Hospital, Texas A&M HSC College of Medicine, Temple, TX, USA, for their critical comments.Financial & competing interests disclosureS Sadayappan was supported by NIH grants 5P30HL101297 and R01HL105826, and an American Heart Association – Scientist Development Grant (0830311N). S Sadayappan holds a provisional patent to determine the risk factors associated with cMyBP-C degradation and release into human body fluid. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download